No Data
No Data
After Losing 47% in the Past Year, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Institutional Owners Must Be Relieved by the Recent Gain
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $11
Express News | Aldeyra Therapeutics Inc: Clinical Trial Results and Potential New Drug Application Resubmission Expected in Second Half of 2024
Express News | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Host Investor Roundtable QA
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
No Data